The subcutaneous injection formulation of the Alzheimer's disease treatment Leqembi (generic name: lecanemab), 'Leqembi ...
ARespo is advancing programs focused on addressing persistent treatment gaps for individuals living with Alpha-1 Antitrypsin Deficiency (AATD), initially with an emphasis on best-in-class AATD ...
It is a formulation that allows the cancer immunotherapy drug Keytruda to be administered via subcutaneous injection rather ...
Supported by phase 3 PREVAIL data, the dual-binding nanobody complement C5 inhibitor provides rapid, sustained functional ...
Dosing flexibility across weekly, biweekly, and monthly schedules gives Viking a structural advantage that currently approved ...
Researchers evaluated the efficacy and safety of weekly retatrutide injections in adults with painful knee osteoarthritis and ...
Leqembi home injection launched in Japan on Nov. 13 as Eisai's lecanemab pen listed at 27,141 yen per 250 mg kit, about 339 ...
The once weekly self-injected treatment is the first dual-binding nanobody C5 inhibitor approved for adults with AChR ...
A pharmacovigilance study integrating post-marketing databases, machine learning, and transcriptomics identified a ...
As osteoporosis treatment options expand, determining the optimal sequence of therapies has become a critical clinical ...
U.S. drugmaker Merck (MSD) has seen its patent burden over the cancer immunotherapy "Keytruda Qlex" ease further after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results